NanoViricides Advances Broad-Spectrum Antiviral Drug Development

SHELTON, CT / ACCESSWIRE / July 1, 2024 / NanoViricides, Inc. (NYSE American: NNVC) announces progress in developing its broad-spectrum antiviral nanomedicines. The focus is on NV-387, their leading antiviral candidate, which has completed Phase I clinical trials with no adverse events reported.

NV-387 has demonstrated significant effectiveness against various viruses, including RSV, Influenza, and COVID-19, in animal models. The company is advancing to Phase II studies, specifically targeting RSV treatment in pediatric patients.

The market potential for NV-387 is substantial, with an estimated size of $16 billion over the next three years across RSV, Influenza, and COVID-19.

NanoViricides also plans to license its drug candidates and seek non-dilutive funding for biodefense drug development. The company maintains a strong manufacturing capability, essential for bringing NV-387 to market upon FDA approval.

In addition to NV-387, NanoViricides is developing NV-HHV-1 for treating herpesvirus infections. The company believes its unique technology platform will continue to yield valuable drug candidates.